On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Evidence in stroke care should not be repurposed as proof of general cognitive enhancement.
What the evidence shows
Large acute-stroke study
CASTA enrolled 1,070 patients with acute ischemic stroke. Its combined confirmatory functional endpoint did not significantly differ between Cerebrolysin and placebo. Post-hoc subgroup trends do not overturn that primary finding. [1]
Rehabilitation is a different question
The exploratory CARS trial reported better arm-function recovery alongside early rehabilitation than placebo. Its authors called for confirmation in a larger trial. Differences in timing, background therapy, and endpoints matter when comparing this with CASTA. [2]
What remains unknown
Which patients might benefit, how durable improvements are, and how findings compare with established rehabilitation remain questions for condition-specific review.
Safety
Trial safety cannot be generalized to self-treatment
CASTA monitored adverse events during hospital-based treatment and follow-up. This does not validate unsupervised administration, healthy-person use, or substitution for time-sensitive stroke care. [1]
Match the preparation
The clinical trials concern the named Cerebrolysin preparation. Results should not be assumed to apply to another peptide mixture simply because it is described as neurotrophic. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Do these findings mean it improves focus in healthy people?
No. A trial in stroke survivors addresses recovery after brain injury, not ordinary concentration or memory in healthy adults.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Cerebrolysin: CASTA acute stroke trial2012 · Original research · PubMed
- Cerebrolysin: CARS rehabilitation trial2016 · Original research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.